ClinicalTrials.gg
CompletedNCT00291577Updated Dec 23, 2009Results posted

Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer

A Phase 1 interventional study of Sunitinib (Sutent) and Taxotere in Breast Neoplasms, sponsored by Pfizer. Completed at 3 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-23.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 29 studies testing sunitinib in Breast Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Sunitinib · Breast Neoplasms.

Enrollment
20th of 29
22 · median 60
Started
2006
with 5 others
Phase 1
4 of 29
none open now
Registered
6th of 29
by date
Lead sponsor
14 of 29
Pfizer

Among the 29 studies testing sunitinib in Breast Neoplasms, this one is the 20th largest by enrollment, is one of 6 that started in 2006, is one of 4 in phase 1, and was the 6th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 29 studies testing sunitinib in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sunitinib

Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing sunitinib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

Keywords

  • advanced
  • sunitinib (Sutent)
  • docetaxel
  • Phase 1B
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breast cancer with evidence of unresectable, locally recurrent or disease
  • Candidate for treatment with docetaxel

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy in the advanced disease setting
  • Inflammatory breast cancer
  • positive disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    1

    Drug: Sunitinib (Sutent) · Drug: Taxotere

Interventions

  • Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision

    Also known as: Sutent

  • Taxotere 75 mg/m2 iv, once every 3 weeks

06

What researchers measure

Primary outcomes

  1. Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

    Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation.

    Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose

  2. Maximum Observed Plasma Concentration (Cmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

    Mean Cmax = maximum plasma concentration for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured as nanograms per milliliter (ng/mL); collected C1D2, C2D3. Paired observation; Cmax dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).

    Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose

  3. Area Under the Plasma Concentration-time Profile From Time Zero (0) to 24 Hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

    Mean AUC24 = area under plasma concentration-time profile from time 0 to 24 hours for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured in nanograms times hour per milliliter (ng\*hr/mL); collected C1D2, C2D3. Paired observation; AUC24 dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).

    Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose

  4. Area Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

    Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D2, C2D3. Data did not allow calculation of AUClast; not summarized; AUC summarized in outcome measure: Area under the plasma concentration-time curve from time zero (0) to 24 hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters.

    Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose

  5. Trough Plasma Concentration (Ctrough) at Time Zero (0): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

    Mean Ctrough=plasma concentration-time profile at time 0 (predose); collected C1D2, C1D15, and C2D1. Calculated by setting concentration values below the limit of quantification to zero.

    Time frame: 0 hour postdose

  6. Time to Reach Maximum Plasma Concentration (Tmax): Docetaxel PK Parameters

    Median Tmax = time to maximum plasma concentration (Cmax) for Docetaxel; collected C1D1, C2D1. Paired observation.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose

  7. Maximum Observed Plasma Concentration (Cmax): Docetaxel PK Parameters

    Mean Cmax = maximum plasma concentration for Docetaxel; collected C1D1, C2D1. Paired observation; Cmax dose corrected (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose

  8. Area Under the Plasma Concentration-time Curve From Time Zero (0) to 24 Hours (AUC24): Docetaxel PK Parameters

    Mean AUC24 = area under the plasma concentration-time profile from time 0 to 24 hours; collected C1D1, C2D1. Paired observation.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose

  9. Area Under the Plasma Concentration-time Curve From Time Zero (0) to 48 Hours (AUC48): Docetaxel PK Parameters

    Mean AUC48 = area under the plasma concentration-time profile from time 0 to 48 hours; collected C1D1, C2D1. Paired observation.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose

  10. Area Under the Curve From Time 24 Hours to 48 Hours (AUC24_48) : Docetaxel PK Parameters

    Mean AUC24_48 = area under the plasma concentration-time profile from 24 to 48 hours; collected C1D1, C2D1. Paired observation.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose

  11. Area Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Docetaxel PK Parameters

    Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D1, C2D1. Paired observation.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose

  12. Plasma Elimination Half-life (t1/2): Docetaxel PK Parameters

    Mean Thalf (t1/2) = terminal elimination half life; collected C1D1, C2D1. Paired observation.

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose

Secondary outcomes

  1. Progression-Free Survival (PFS) Based on Investigator Assessment

    Median time (50 percent \[%\]) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first; based on Investigator assessment. PFS calculated as (Weeks) = (first event date minus first dose date plus 1) divided by 7.

    Time frame: First dose of study treatment until progressive disease

  2. Number of Subjects With Objective Response of Complete Response or Partial Response Based on Investigator Assessment

    Number of subjects with objective response based on Investigator assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.

    Time frame: First dose of study treatment until at least 4 weeks after confirmed response or partial response

  3. Number of Subjects With Clinical Benefit of Complete Response, Partial Response, or Stable Disease Based on Investigator Assessment

    Number of subjects with clinical benefit based on Investigator assessment of confirmed complete response (CR), partial response (PR), or stable disease (SD) according to RECIST for at least 24 weeks on study.

    Time frame: First dose of study treatment until at least 24 weeks on study

  4. Duration of Tumor Response Based on Investigator Assessment

    Median duration (50%) of tumor response based on Investigator assessment for a subgroup of subjects with objective disease response: who have not progressed or died due to any cause; with a response and subsequent progression or death due to any cause for duration of response (DR). DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.

    Time frame: Start of first confirmed CR or PR to first confirmed progression or death

07

Results

Posted Dec 23, 2009

Participant flow

Participant flow — Overall Study
MilestoneSunitinib in Combination With Docetaxel
Started22
Completed1
Not completed21
Withdrew: Adverse event1
Withdrew: Other4
Withdrew: Withdrawal by subject2
Withdrew: Lack of efficacy14

Outcome measures

PrimaryTime to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation.

Time frame:
1, 2, 4, 6, 8, 12, 24 hours postdose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
hoursSunitinib in Combination With Docetaxel
SU011248 C1D26.0 (4.0 to 24.0)
SU011248 C2D36.0 (2.0 to 8.0)
SU012662 C1D26.0 (2.0 to 24.0)
SU012662 C2D36.0 (4.0 to 24.0)
Total drug C1D26.0 (2.0 to 24.0)
Total drug C2D36.0 (2.0 to 8.0)
PrimaryMaximum Observed Plasma Concentration (Cmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

Mean Cmax = maximum plasma concentration for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured as nanograms per milliliter (ng/mL); collected C1D2, C2D3. Paired observation; Cmax dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).

Time frame:
1, 2, 4, 6, 8, 12, 24 hours postdose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
ng/mLSunitinib in Combination With Docetaxel
SU011248 C1D229.17 ± 7.906
SU011248 C2D329.49 ± 7.910
SU012662 C1D25.07 ± 2.385
SU012662 C2D35.91 ± 2.251
Total drug C1D234.05 ± 9.312
Total drug C2D334.69 ± 8.941
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 98.89 · 90% CI 80.34 to 121.73Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 81.96 · 90% CI 59.76 to 112.41Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 97.81 · 90% CI 80.44 to 118.94Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
PrimaryArea Under the Plasma Concentration-time Profile From Time Zero (0) to 24 Hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

Mean AUC24 = area under plasma concentration-time profile from time 0 to 24 hours for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured in nanograms times hour per milliliter (ng\*hr/mL); collected C1D2, C2D3. Paired observation; AUC24 dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).

Time frame:
1, 2, 4, 6, 8, 12, 24 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration-time Profile From Time Zero (0) to 24 Hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
ng*hr/mLSunitinib in Combination With Docetaxel
SU011248 C1D2486.38 ± 132.439
SU011248 C2D3479.80 ± 128.718
SU012662 C1D282.21 ± 33.204
SU012662 C2D396.88 ± 30.513
Total drug C1D2568.78 ± 152.106
Total drug C2D3567.43 ± 145.952
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 101.23 · 90% CI 82.75 to 123.83Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 81.72 · 90% CI 62.40 to 107.04Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 100.00 · 90% CI 82.95 to 120.56Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
PrimaryArea Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D2, C2D3. Data did not allow calculation of AUClast; not summarized; AUC summarized in outcome measure: Area under the plasma concentration-time curve from time zero (0) to 24 hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters.

Time frame:
1, 2, 4, 6, 8, 12, 24 hours postdose
Reported as:
Mean · ng*hr/mL

No measurements were reported for this outcome.

PrimaryTrough Plasma Concentration (Ctrough) at Time Zero (0): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters

Mean Ctrough=plasma concentration-time profile at time 0 (predose); collected C1D2, C1D15, and C2D1. Calculated by setting concentration values below the limit of quantification to zero.

Time frame:
0 hour postdose
Reported as:
Mean · ng/mL
Trough Plasma Concentration (Ctrough) at Time Zero (0): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
ng/mLSunitinib in Combination With Docetaxel
SU011248 C1D15 (n=18)52.06 ± 23.05
SU011248 C2D1 (n=11)5.00 ± 5.14
SU012662 C1D15 (n=18)21.75 ± 8.85
SU012662 C2D1 (n=11)4.88 ± 3.52
Total drug C1D2 (n=12)0.20 ± 0.00
Total drug C1D15 (n=18)73.81 ± 29.00
Total drug 21D1 (n=11)9.87 ± 8.36
PrimaryTime to Reach Maximum Plasma Concentration (Tmax): Docetaxel PK Parameters

Median Tmax = time to maximum plasma concentration (Cmax) for Docetaxel; collected C1D1, C2D1. Paired observation.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax): Docetaxel PK Parameters
hoursSunitinib in Combination With Docetaxel
C1D10.70 (0.5 to 1.0)
C2D10.77 (0.5 to 1.0)
PrimaryMaximum Observed Plasma Concentration (Cmax): Docetaxel PK Parameters

Mean Cmax = maximum plasma concentration for Docetaxel; collected C1D1, C2D1. Paired observation; Cmax dose corrected (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax): Docetaxel PK Parameters
ng/mLSunitinib in Combination With Docetaxel
C1D12932.00 ± 903.952
C2D12955.38 ± 853.925
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 99.18 · 90% CI 78.73 to 124.95Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero (0) to 24 Hours (AUC24): Docetaxel PK Parameters

Mean AUC24 = area under the plasma concentration-time profile from time 0 to 24 hours; collected C1D1, C2D1. Paired observation.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve From Time Zero (0) to 24 Hours (AUC24): Docetaxel PK Parameters
ng*hr/mLSunitinib in Combination With Docetaxel
C1D12918.09 ± 594.227
C2D13101.69 ± 778.041
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 94.98 · 90% CI 78.73 to 114.58Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
SecondaryProgression-Free Survival (PFS) Based on Investigator Assessment

Median time (50 percent \[%\]) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first; based on Investigator assessment. PFS calculated as (Weeks) = (first event date minus first dose date plus 1) divided by 7.

Time frame:
First dose of study treatment until progressive disease
Reported as:
Median · weeks
Progression-Free Survival (PFS) Based on Investigator Assessment
weeksSunitinib in Combination With Docetaxel
Progression-Free Survival (PFS) Based on Investigator Assessment34.9 (28.1 to 55.6)
SecondaryNumber of Subjects With Objective Response of Complete Response or Partial Response Based on Investigator Assessment

Number of subjects with objective response based on Investigator assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.

Time frame:
First dose of study treatment until at least 4 weeks after confirmed response or partial response
Reported as:
Number · participants
Number of Subjects With Objective Response of Complete Response or Partial Response Based on Investigator Assessment
participantsSunitinib in Combination With Docetaxel
Number of Subjects With Objective Response of Complete Response or Partial Response Based on Investigator Assessment14 (90.9 to —)
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Rate (percent): 73.7 · 95% CI 48.8 to 90.9Two-sided Confidence Interval (CI) (%) from exact method based on F distribution.
SecondaryNumber of Subjects With Clinical Benefit of Complete Response, Partial Response, or Stable Disease Based on Investigator Assessment

Number of subjects with clinical benefit based on Investigator assessment of confirmed complete response (CR), partial response (PR), or stable disease (SD) according to RECIST for at least 24 weeks on study.

Time frame:
First dose of study treatment until at least 24 weeks on study
Reported as:
Number · participants
Number of Subjects With Clinical Benefit of Complete Response, Partial Response, or Stable Disease Based on Investigator Assessment
participantsSunitinib in Combination With Docetaxel
Number of Subjects With Clinical Benefit of Complete Response, Partial Response, or Stable Disease Based on Investigator Assessment17
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Rate (percent): 89.5 · 95% CI 66.9 to 98.7Two-sided CI (%) from exact method based on F distribution.
SecondaryDuration of Tumor Response Based on Investigator Assessment

Median duration (50%) of tumor response based on Investigator assessment for a subgroup of subjects with objective disease response: who have not progressed or died due to any cause; with a response and subsequent progression or death due to any cause for duration of response (DR). DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.

Time frame:
Start of first confirmed CR or PR to first confirmed progression or death
Reported as:
Median · weeks
Duration of Tumor Response Based on Investigator Assessment
weeksSunitinib in Combination With Docetaxel
Duration of Tumor Response Based on Investigator Assessment28.7 (22.7 to 69.6)
PrimaryArea Under the Plasma Concentration-time Curve From Time Zero (0) to 48 Hours (AUC48): Docetaxel PK Parameters

Mean AUC48 = area under the plasma concentration-time profile from time 0 to 48 hours; collected C1D1, C2D1. Paired observation.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Reported as:
Mean · ng*hr.mL
Area Under the Plasma Concentration-time Curve From Time Zero (0) to 48 Hours (AUC48): Docetaxel PK Parameters
ng*hr.mLSunitinib in Combination With Docetaxel
C1D13167.53 ± 658.124
C2D13326.98 ± 775.599
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 95.57 · 90% CI 79.90 to 114.32Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
PrimaryArea Under the Curve From Time 24 Hours to 48 Hours (AUC24_48) : Docetaxel PK Parameters

Mean AUC24_48 = area under the plasma concentration-time profile from 24 to 48 hours; collected C1D1, C2D1. Paired observation.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time 24 Hours to 48 Hours (AUC24_48) : Docetaxel PK Parameters
ng*hr/mLSunitinib in Combination With Docetaxel
C1D1249.45 ± 108.911
C2D1225.29 ± 96.657
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 112.39 · 90% CI 81.05 to 155.85Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
PrimaryArea Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Docetaxel PK Parameters

Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D1, C2D1. Paired observation.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Reported as:
Mean · ng*hr/mL
Area Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Docetaxel PK Parameters
ng*hr/mLSunitinib in Combination With Docetaxel
C1D13159.58 ± 675.834
C2D13304.48 ± 769.011
Statistical analysis
  • Sunitinib in Combination With Docetaxel · Ratio of adjusted geometric means: 95.79 · 90% CI 79.82 to 114.96Ratio percent (%) (Test/Reference) of adjusted geometric means; values have been back-transformed from the log scale.
PrimaryPlasma Elimination Half-life (t1/2): Docetaxel PK Parameters

Mean Thalf (t1/2) = terminal elimination half life; collected C1D1, C2D1. Paired observation.

Time frame:
0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Reported as:
Mean · hours
Plasma Elimination Half-life (t1/2): Docetaxel PK Parameters
hoursSunitinib in Combination With Docetaxel
C1D122.55 ± 5.914
C2D124.88 ± 10.651

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sunitinib in Combination With Docetaxel—11/22 (50%)21/22 (95.5%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventSunitinib in Combination With Docetaxel
Febrile neutropeniaBlood and lymphatic system disorders4/22
NeutropeniaBlood and lymphatic system disorders2/22
LeukopeniaBlood and lymphatic system disorders1/22
StomatitisGastrointestinal disorders1/22
FatigueGeneral disorders1/22
Oedema peripheralGeneral disorders1/22
PyrexiaGeneral disorders1/22
JaundiceHepatobiliary disorders1/22
Back painMusculoskeletal and connective tissue disorders1/22
Musculoskeletal painMusculoskeletal and connective tissue disorders1/22
Most frequent other events
Showing 10 of 59
Most frequent other events
EventSunitinib in Combination With Docetaxel
DiarrhoeaGastrointestinal disorders13/22
AlopeciaSkin and subcutaneous tissue disorders12/22
NauseaGastrointestinal disorders11/22
StomatitisGastrointestinal disorders11/22
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders11/22
NeutropeniaBlood and lymphatic system disorders10/22
FatigueGeneral disorders10/22
Mucosal inflammationGeneral disorders9/22
HeadacheNervous system disorders8/22
Abdominal pain upperGastrointestinal disorders7/22

Baseline characteristics

Age, Customized
Age, Customized(participants)Sunitinib in Combination With Docetaxel
18 to 44 years3
45 to 64 years13
> = 65 years6
Sex: Female, Male
Sex: Female, Male(Participants)Sunitinib in Combination With Docetaxel
Female21
Male1
08

Study locations

3 sites
  • Pfizer Investigational Site
    Bruxelles, 1000, Belgium
  • Pfizer Investigational Site
    Milano, 20133, Italy
  • Pfizer Investigational Site
    Stockholm, 171 76, Sweden
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Oct 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2006
First posted
Feb 14, 2006
Start
Jul 2006
Primary completionActual
Oct 2008
CompletionActual
Feb 2009
Results first posted
Dec 23, 2009
Last update
Dec 23, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00291577
Lead sponsor
Pfizer
First posted
Feb 14, 2006
Start date
Jul 2006
Primary completion
Oct 2008
Completion
Feb 2009
Results posted
Dec 23, 2009
Last update
Dec 23, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sunitinib · Docetaxel

Start the discussion